The ligand-activated transcription factor aryl hydrocarbon receptor (AHR) participates in the differentiation of FoxP3 + T reg , Tr1 cells, and IL-17-producing T cells (Th17). Most of our understanding on the role of AHR on the FoxP3 + T reg compartment results from studies using the toxic synthetic chemical 2,3,7,8-tetrachlorodibenzo-p-dioxin. Thus, the physiological relevance of AHR signaling on FoxP3 + T reg in vivo is unclear. We studied mice that carry a GFP reporter in the endogenous foxp3 locus and a mutated AHR protein with reduced affinity for its ligands, and found that AHR signaling participates in the differentiation of FoxP3 + T reg in vivo. Moreover, we found that treatment with the endogenous AHR ligand 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) given parenterally or orally induces FoxP3 + T reg that suppress experimental autoimmune encephalomyelitis. ITE acts not only on T cells, but also directly on dendritic cells to induce tolerogenic dendritic cells that support FoxP3 + T reg differentiation in a retinoic acid-dependent manner. Thus, our work demonstrates that the endogenous AHR ligand ITE promotes the induction of active immunologic tolerance by direct effects on dendritic and T cells, and identifies nontoxic endogenous AHR ligands as potential unique compounds for the treatment of autoimmune disorders. R egulatory T cells (T reg ) that express the transcription factor FoxP3 control immune autoreactivity in healthy individuals (1). FoxP3 + T reg are generated in the thymus (natural T reg , nT reg ) and also in the periphery (induced T reg , iT reg ). The importance of FoxP3 + T reg for immunoregulation is highlighted by the immune disorders that result from their depletion or loss of function in both mice and humans (1). Conversely, the induction of FoxP3 + T reg is viewed as a promising approach for the treatment of immunemediated disorders (2).
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We (3) and others (4) (5) (6) (7) (8) have found that the ligand-activated transcription factor aryl hydrocarbon receptor (AHR) controls the differentiation of T reg , Tr1 cells (9) , and IL-17-producing T cells (Th17) in vitro and in vivo. AHR activation by its high-af- 
Foxp3
+ T reg are functional and suppress the development of experimental autoimmune encephalomyelitis (EAE) (3), experimental autoimmune uveoretinitis (7) , and spontaneous autoimmune diabetes (10) .
TCDD is a valuable tool to study the immunological effects of AHR activation, but TCDD is not a natural AHR ligand and its toxicity rules out its therapeutic use. Thus, it is not yet known whether there is a physiological role for AHR in FoxP3 + T reg , and whether nontoxic AHR ligands exist which can expand FoxP3 + T reg in vivo to treat autoimmunity. To address these questions, we used mice carrying a GFP reporter in foxp3 and a mutant AHR protein with reduced affinity for its ligands. In addition, we investigated the effect and mechanisms of action of the nontoxic mucosal AHR ligand 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) on FoxP3 + T reg both in vitro and in vivo in the model of EAE. (17) . AHR interacts with Stat1 and limits its activation during the differentiation of Th17 cells (5 mice (Fig. S1E) ; no changes were detected in the phosphorylation of Stat5 (Fig. S3) (Fig. 1A) . ITE did not suppress EAE in AHR-d mice, indicating that the effects of ITE on EAE were mediated by AHR (Fig. 1A) . Oral (Fig. 1B ) administration of ITE (200 μg/mice, daily) also suppressed EAE. Although the liver is highly sensitive to the toxic effects of TCDD (19) , ITE administration did not result in liver toxicity (Table S1 ). Thus, ITE suppresses EAE by an AHR-dependent mechanism that does not involve toxicity and is active orally.
Results

AHR Activation by Endogenous Ligands
EAE is an autoimmune disease driven by Th1 and Th17 cells. To study the suppression of EAE by AHR activation with ITE, we analyzed the T-cell recall response to the encephalitogenic peptide MOG . ITE treatment suppressed the recall proliferative response to MOG (Fig. 1C) ; no differences were seen upon activation with mitogenic antibodies to CD3 (Fig. S4) , indicating that ITE treatment did not result in global immunosuppression. Moreover, draining lymph node cells from ITE-treated mice secreted higher amounts of TGF-β1 and IL-10 and lower amounts of IFN-γ and IL-17 upon activation with MOG (Fig. 1D) .
To investigate the therapeutic potential of ITE, we used the relapsing-remitting model of EAE induced in SJL mice by immunization with PLP 139-151 . We initiated treatment with ITE on day 17 (daily, 200 μg/mice, intraperitoneally), during the remission that followed the first attack. Treatment with ITE reduced the disability in the relapse and the encephalitogenic response to PLP 139-151 ( Fig. 1 E and F) . Thus, AHR activation by ITE suppresses the encephalitogenic T-cell response and EAE in both preventive and therapeutic experimental paradigms.
AHR Activation by the Nontoxic Endogenous Ligand ITE Expands the FoxP3
+ T reg Compartment. We (3) and others (4, 5, 7, 10) (Fig. 2D) , which was abrogated by the removal of FoxP3:GFP + T cells (Fig. 2D) , suggesting that AHR activation by ITE induces FoxP3 + T reg that suppress the encephalitogenic CD4 + T-cell response. We performed adoptive transfer experiments to study the role of T reg on the suppression of EAE by ITE administration. The transfer of 5 × 10 6 CD4 + T cells from ITE-treated mice before immunization with MOG resulted in a significant suppression of EAE; CD4 + T cells from control-treated mice had no effect (Fig. 2E) . The suppressive activity of CD4 + T cells from ITE-treated mice was lost when CD4 + CD25 + T cells were depleted (Fig. 2E) . Thus, AHR activation by ITE results in the generation of CD4 + Foxp3 + T reg cells that suppress the encephalitogenic response.
AHR Activation by the Nontoxic Endogenous Ligand ITE Induces
Tolerogenic Dendritic Cells. Dendritic cells (DCs) control the activation and polarization of T cells (21) and the FoxP3 + T reg compartment in vivo (22) . Based on the reported expression of functional AHR by DCs (4, 23, 24), we studied the effects of ITE on DCs. To determine if DCs are affected by treatment with ITE in vivo, we immunized WT mice with MOG in complete Freund's adjuvant (CFA), treated them daily with ITE or vehicle (administered intraperitoneally), and analyzed splenic DCs by FACS 10 d after immunization. Splenic DCs from ITE-treated mice (DC ITE ) showed slightly decreased CD86 expression and an increased CD103 expression; no changes in the expression of MHC-I, MHC-II, CD40, and CD80 or the size of the splenic DC compartment were observed (Fig. 3A) . We did find, however, that DC ITE produced lower amounts of the proinflammatory cytokines IL-1β, IL-6, IL-12, IL-23, and osteopontin, and more TGF-β1 and IL-10 (Fig. 3B) . DC ITE also showed a decreased ability to trigger the proliferation of naive 2D2 + T cells with MOG (Fig.  3C ). In addition, naive 2D2 + T cells activated with DC ITE and MOG secreted lower amounts of IL-17 and IFN-γ, and more IL-10 and TGF-β1 (Fig. 3D) . Hence, treatment with the AHR ligand ITE induces tolerogenic DCs in vivo. FoxP3 + T reg can induce a tolerogenic phenotype in DCs (25). Thus, it is possible that AHR activation by ITE in vivo modifies the activity of DCs indirectly, as a result of the expansion of the FoxP3 + T reg compartment. To investigate if the tolerogenic phenotype of DC ITE was a result of the direct effects of AHR activation by ITE on DCs, we generated bone marrow-derived DC (BM-DC) (26) and treated them with ITE 100 nM or vehicle during the last 24 h of their differentiation. Treatment with ITE did not affect the number or the phenotype of BM-DC at the end of the culture (Fig. S6A) . However, purified ITE-treated CD11c + BM-DC (BM-DC ITE ) showed a decreased expression of the proinflammatory cytokines IL-1β, IL-6, IL-12, IL-23, and osteopontin, and a concomitant increase in the expression of TGF-β1 and IL-10 (Fig. S6B) . Moreover, BM-DC ITE showed a reduced ability to activate 2D2 T cells with MOG and trigger the production of IL-17 or IFN-γ (Fig. S6 C and  D) . Conversely, 2D2 T cells activated with BM-DC ITE and MOG produced increased levels of IL-10 and TGF-β1 (Fig.  S6D) or antibodies to CD3. We found that DC ITE showed an increased ability to promote the differentiation of FoxP3 + iT reg upon activation with MOG or antibodies to CD3 and TGF-β1 and IL-2 (Fig. 4A) . Similarly, BM-DC ITE were more efficient at inducing the differentiation of FoxP3 + T reg and showed a significant decrease in their ability to promote Th17 differentiation (Fig. 4B) . These effects were mediated by the activation of AHR by ITE, as they were not observed using BM-DC ITE differentiated from AHR-d mice. Thus, AHR activation by ITE induces tolerogenic DCs that promote the differentiation of FoxP3 + T reg . It has been recently reported that DCs interfere with the development of Th17 cells and promote the differentiation of FoxP3 + iT reg by means of the production of retinoic acid (RA) (11, 28, 29) . The synthesis of RA is controlled by retinal dehydrogenases, which are encoded by members of the Aldh1a gene family (30) . To investigate the role of RA biosynthesis in the tolerogenic phenotype of DC ITE , we measured the expression of aldh1a1 and aldh1a2 in DC ITE by qPCR. DC ITE were found to express significantly higher levels of aldh1a1, but no changes were detected on the expression of aldh1a2 (Fig. 5C ). Similar results were found when the expression of aldh1a1 and aldh1a2 was analyzed on BM-DC ITE cells (Fig. S7) . To investigate the significance of RA in the ability of DC ITE to promote the differentiation of FoxP3 + T reg , we used the specific inhibitor of RA signaling LE135. We found that the ability of DC ITE to induce the differentiation of FoxP3 + T reg was significantly reduced in the presence of LE135 (Fig. 4D) ; no effects were observed on the ability of control DCs to promote the differentiation of FoxP3 + T reg . Taken together, these data demonstrate that AHR activation by ITE induces anti-inflammatory DCs that promote iT reg differentiation via the secretion of RA.
Passive Transfer of BM-DC ITE Suppresses EAE. To investigate the relevance of the tolerogenic DCs induced by ITE treatment on the suppression of EAE, we performed adoptive transfer experiments. Control BM-DC and BM-DC ITE were incubated for 1 h with MOG and transferred ip to naive mice (2 × 10 6 per mouse); this procedure was repeated three times, once every 4 d. Four days after the last transfer of BM-DC, EAE was induced. We found that the adoptive transfer of BM-DC ITE from WT mice resulted in a significant suppression of EAE (Fig. 5A) ; no protective effects were observed when control BM-DC or AHR-d BM-DC ITE were transferred (Fig. 5A) . The suppression of EAE by WT BM-DC ITE correlated with the suppression of the encephalitogenic response to MOG (Fig. 5B) . BM-DC and AHR-d BM-DC ITE had no effect on the recall response to MOG (Fig. 5B) . Moreover, mice transferred with WT BM-DC ITE had increased numbers of FoxP3 + T reg than recipients of wild type BM-DC or AHR-d BM-DC ITE , and a concomitant reduction in the frequency of Th1 and Th17 cells (Fig. 5C) . Thus, the DC ITE induced by treatment with ITE contribute to the expansion of FoxP3 + T reg and the suppression of EAE.
Discussion
The induction of FoxP3 + T reg is viewed as a promising approach for the treatment of human autoimmune disorders (2) . Several methods have been described to differentiate and expand human FoxP3 + T reg in vitro, but their ability to produce significant numbers of functional FoxP3 + T reg in a consistent manner is limited (31) . Thus, strategies aimed at the induction of functional FoxP3 + T reg in vivo are more likely to be translated into clinical practice. We and others have shown that AHR activation induces functional FoxP3 + T reg that suppress the development of experimental autoimmunity and transplant rejection (3, 4, 7, 10) ; thus, AHR is an attractive target for the induction of functional FoxP3 + T reg . However, to date, studies on the effect of AHR ligands in models of autoimmunity have mostly focused on TCDD, a synthetic toxin. Because of its lack of toxicity (32), the endogenous AHR ligand ITE is a potential compound to induce functional FoxP3 + T reg in vivo and treat autoimmune diseases. We found an impaired ability of AHR-d CD4 + FoxP3 − T cells to differentiate into FoxP3 + iT reg both in vitro and in vivo. The mutant AHR protein in AHR-d Foxp3 gfp mice displays a significant reduction in its affinity for AHR ligands (13) . Thus, the reduced differentiation of AHR-d CD4 + FoxP3 − T cells into FoxP3 + iT reg suggests that AHR activation in T cells by endogenous ligands plays a physiological role in the differentiation of FoxP3 + iT reg . This interpretation is in agreement with the impaired differentiation of AHR-deficient CD4 + T cells into FoxP3 + iT reg described by Kimura et al. (5) . The specific AHR ligands that modulate T-cell differentiation in vitro and in vivo are, however, still largely unknown.
AHR limits the activation of Stat1 during Th17 differentiation (5), and Stat1 activation antagonizes the differentiation of FoxP3 + iT reg (17) . Hence, our data suggest that by limiting the activation of Stat1, AHR interferes with the antagonistic activity of Stat1 signaling on FoxP3 + T reg differentiation. Note that Stat1 activation interferes with the differentiation of iT reg (17, 33) but not nT reg (33) ; indeed, several cytokines, signaling pathways, and genomic elements have differential contributions to the generation of iT reg and nT reg (34, 35) . The control of Stat1 activation by AHR might preferentially favor the differentiation of FoxP3 + iT reg during an active immune response by interfering with IFN-γ signaling. Together, with the effects of AHR on foxp3 expression (3) and FoxP3 + T reg survival (4), its effects on Stat1 activation might participate in the control of immunopathology during the immune response.
AHR activation has been shown to modulate the function and maturation of DCs (4, 23, 24) and macrophages (36, 37) . Indeed, AHR in macrophages limits LPS-induced inflammation (36, 37) , and AHR in DCs mediates the anti-inflammatory activities of lipoxin A4 (23) . We found that the AHR ligand ITE induces DCs that promote the differentiation of FoxP3 + T reg in a RAdependent manner. Mucosal CD103 + DC promote the differentiation of FoxP3 + T reg via RA (11, 28, 29) , and RA (38) and IL-10 (39) also have autocrine anti-inflammatory effects on DCs. Thus, our results support a model in which AHR activation induces tolerogenic DCs that promote the generation of FoxP3 + T reg via the production of RA and the concomitant down-regulation of proinflammatory cytokines that interfere with FoxP3 + T reg differentiation (12, 14) . Moreover, it is possible that under physiological conditions, endogenous AHR ligands participate in the development of the mucosal CD103 + DC that promote the differentiation of FoxP3 + iT reg . In conclusion, our work demonstrates that the endogenous AHR ligand ITE, given either orally or parenterally, acts on DCs and T cells to promote the induction of functional FoxP3 + T reg that suppress EAE. We recently reported that AHR activation promotes the differentiation of suppressive human regulatory T cells in vitro (40) . Thus, nontoxic endogenous AHR ligands like ITE are potential new compounds for the treatment of autoimmune disorders.
Materials and Methods
Mice and Reagents. Foxp3 gfp knock-in mice have been described (12) . C57BL/ 6-, AHR-d-, SJL-, and RAG-1-deficient mice were purchased from The Jackson Laboratories. All experiments were carried out in accordance with the guidelines of the standing committee of animals at Harvard Medical School. ITE was purchased from Sigma-Aldrich and from Tocris Bioscience.
EAE Induction. EAE was induced by subcutaneous immunization with 100 μg of MOG peptide or 50 μg of PLP 139-151 peptide (HSLGKWLGHPDKF) as described (3).
T-Cell Differentiation in Vitro. Naive CD4 + CD62L high CD44 low Foxp3:GFP − T cells were stimulated for 5 to 6 d (3) using plate-bound antibody to CD3 (145-2C11, 1 μg/mL) plus soluble antibody to CD28 (PV-1, 2 μg/mL) and human TGF-β1 (3 ng/mL, unless otherwise indicated) and mouse IL-2 (50 units/ mL) or mouse IL-6 (30 ng/mL). Alternatively, naive CD4 T cells were activated with BM-DC or purified DC at a 5:1 T cell-to-DC ratio, and activated with soluble antibody to CD3 (0.5 μg/mL) or MOG (20 μg/mL).
Adoptive Transfer Experiments. RAG-1 deficient mice received 1 × 10 6 FACSsorted CD4 + Foxp3 − T cells. One month after transfer, host mice were checked for reconstitution of CD4 + T cells, immunized with MOG in IFA, and 3 wk later, Foxp3:GFP expression was tested in splenocytes by FACS.
Real-Time PCR. Real-time PCR was performed as described (3) . All values were expressed relative to the expression of GAPDH.
Cell Proliferation and Cytokine Production. Cells were cultured in serum-free X-VIVO 20 media (BioWhittaker) and cell proliferation and cytokine production were analyzed as described (3).
FACS. For intracellular cytokine staining, cells were stimulated with PMA (50 ng/mL) (Sigma-Aldrich), ionomycin (1 μg/mL) (Calbiochem), and GolgiStop (BD Biosciences) for 4 h and stained, as described (3) . For the analysis of Stat phosphorylation, T cells were activated with plate bound antibodies to CD3 and CD28, with or without the addition of cytokines, and 48 h after the initiation of the cultures the cells were stained with antibodies to Stat1 or Stat5, following the manufacturer's instructions (BD Biosciences).
Generation of BM-DC. Isolated BM cells were cultured for 6 d in the presence of IL-4 (10 ng/mL) and GM-CSF (10 ng/mL). On day 6, the cells were treated with ITE or vehicle, and 24 h later, they were analyzed by FACS or purified with CD11c + beads (Miltenyi).
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